Table 2.
WHO – Pipeline Zika virus (ZIKV) vaccines (in preclinical development) (last updated January 2017) January 2017)
| Platform | Candidate vaccine name | Developer/Collaborators | Replicating virus (Yes/No) | Antigen | Adjuvant |
|---|---|---|---|---|---|
| Inactivated whole target organism | BK1603 | BIKEN | No | ZIKV full genome | To be determined |
| Inactivated whole target organism | Bio-Manguinhos in house development and Sanofi Pasteur/WRAIR (discontinued in 2017) | No | ZIKV full genome | Alum | |
| Recombinant subunit (non- VLP) | Bio-Manguinhos partnership | No | ZIKV E protein | Alum | |
| Recombinant viral vector | Bio-Manguinhos/Aggeu Magalhaes (FIOCRUZ) | Yes | PrM/E and PrM/E/NS1 | None | |
| Live, attenuated recombinant virus | Brazilian Ministry of Health agreement with University of Texas | Yes | rZIKV | None | |
| rZIKV NS1 | |||||
| Inactivated whole target organism | Butantan ZIKV | Butantan | No | ZIKV full genome | Alum |
| Live, attenuated target organism | Butantan attenuated ZIKV | Butantan | ZIKV full genome | None | |
| Inactivated virus + aluminum adjuvant | ZIKV | Emergent BioSolutions | No | ZIKV full genome | Aluminum |
| Recombinant viral vector | GEO-ZM05 | GeoVax/University of Georgia/CDC Atlanta, US | No | ZIKV PrM/E + NS1 | None |
| SAM | WT | GSK-NIH | Yes | ZIKV prM/E | |
| SAM | CO | GSK-NIH | Yes | ZIKV prM/E | |
| SAM | VRC_5283 | GSK-NIH | Yes | ZIKV prM/E | |
| SAM | VRC_5288 | GSK-NIH | Yes | ZIKV prM/E | |
| Recombinant subunit (non-VLP) | ZIK-80E | Hawaii Biotech, Inc. | No | ||
| Recombinant subunit VLP (non-fusion) | ZIKVLP | Institut Pasteur Shanghai, China | No | ||
| Recombinant viral vector | NI.LV-ZIK | Institut Pasteur, Paris, France | No | ZIKV prM/E | None |
| Recombinant viral vector | ChAdOx1-Zk | Jenner Institute | ZIKV prM/E | None | |
| Inactivated whole target organism | KAKETSUKEN ZIKV | Kaketsuken | No | ZIKV full genome | TBD |
| Inactivated whole target organism | NewLink Genetics | No | ZIKV prM/E + NS1 | TBD | |
| Recombinant subunit VLP (fusion) | NewLink Genetics | No | ZIKV prM-E | TBD | |
| Live, attenuated target organism | rZIKV/D2D30 | NIAID | Yes | ZIKV prM/E | None |
| Live, attenuated target organism | rZIKV/D4D30 | NIAID | Yes | ZIKV prM/E | None |
| Live, attenuated target organism | rZIKVD30 | NIAID | Yes | ZIKV full genome | None |
| Recombinant viral vector | NIAID | Yes | None | ||
| Sf9 cells/Baculo | ZIKV envelope dimers (EnvD) | Novavax, Inc. | No | ZIKV E protein | Matrix M adjuvant or aluminum hydroxide |
| nanoDNA/ZIKA-LAMP chimera construct | LAMP-ZIKA nanoDNA | Pharos Biologicals | No | ZIKV prM/E | |
| Recombinant subunit (non-VLP) | ZIKA recombinant | Protein Sciences/Sinergium Biotech/Lab Liomont | No | ZIKV E protein | Aluminum based |
| Peptide | Replikins Zika Vaccine and Bocker | Replikins Ltd. | No | Synthetic Peptides | None |
| Recombinant viral vector | Chimerivax-Zika | Sanofi Pasteur | ZIKV prM/E + NS1 | None | |
| Recombinant viral vector | SCV-CHIKV+ZIKV+YF | Sementis Ltd. | No | ZIKV, yellow fever, and CHIKV surface antigens | None |
| Recombinant viral vector | SCV-CHIKV+ZIKV | Sementis Ltd. | No | ZIKV and CHIKV surface antigens | None |
| Recombinant viral vector | SCV-ZIKV | Sementis Ltd. | No | ZIKV surface antigens | None |
| Inactivated whole target organism | Takeda | No | ZIKV full genome | Alum | |
| Subunit | Tours University | No | |||
| VLP HBV-Zika | |||||
| Prime-boost | U1187 INSERM (CYROI, La Reunion) | ||||
| Live attenuated + ZIKV exosome | |||||
| Inactivated whole target organism | Valneva | No | ZIKV full genome | Aluminum hydroxide | |
| Recombinant viral vector | VXA-Zikavax | Vaxart | ZIKV prM/E | ||
| VLP | VBI-2501A | VBI Vaccines | No | ZIKV E + NS1 | |
| DNA | WRAIR/BIDMC/Harvard | No | ZIKV prM/E | ||
| Recombinant viral vector | WRAIR/BIDMC/Harvard | ZIKV prM/E |
BIDMC Beth Israel Deaconess Medical Center, BIKEN Research Foundation for Microbial Diseases of Osaka University, CDC Centers for Disease Control and Prevention, CHIKV Chikungunya virus, GSK GlaxoSmithKline, LAMP loop-mediated isothermal amplification, NIH National Institutes of Health, NIAID National Institute of Allergy and Infectious Diseases, SAM self-amplifying mRNA, SCV Sementis Copenhagen vector, VLP virus-like particles, WRAIR Walter Reed Army Institute of Research, YF Yellow fever, ZIKV Zika virus